- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04331613
Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS
Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS)
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Beijing, China
-
Beijing, Beijing, China, China, 100000
- Recruiting
- Beijing Youan Hospital, Capital Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Chinese patients, aged 18 to 70 years old, males or females;
- Diagnosis of COVID-19, and confirm by chest CT scan;
According to the diagnosis and treatment plan for the novel coronavirus disease (COVID-19) (trial version 5) issued by the National Health Commission (NHC) on the diagnostic criteria for severe or critical ill COVID-19 patients including the patients with acute respiratory distress syndrome (ARDS), the specific diagnostic criteria are:
Severely ill patients should meet all of the following:
- 1. Respiratory distress, RR ≥ 30 times/min.
- 2. In a resting state (without oxygen supplementation), oxygen saturation ≤ 93%.
- 3. Partial arterial oxygen pressure (PaO2) / oxygen absorption concentration (FiO2) ≤ 300 mmHg (1 mmHg = 0.133 kpa). High altitude (above sea level 1000 m) area should be calibrated for PaO2/FiO2 according to the following method: PaO2/FiO2*[atmospheric pressure (mmHg)/760]. Patients with obvious progress in lung lesions by chest CT within 24-48 hours should be counted as the server cases.
Critically ill patients should meet one of the following :
- 1. Respiratory failure, the mechanical ventilation required.
- 2. Shock.
- 3. Associated with other organ failure, ICU needed for monitoring and management.
- Voluntarily participate in the study, agree to comply with the requirements of the clinical trial protocol, and sign the informed consent.
Exclusion criteria:
- Patients with a history of transplantation of cells or organ(s).
- Patients with a history of malignancy or pathology indicating severe atypical hyperplasia.
- Patients without life expectancy of 48 hours.
- Patients with moderate to severe liver failure (Childs Pugh scores > 12).
- Patients with cardiogenic pulmonary edema.
- Patients with a history of deep vein thrombosis or pulmonary embolism within 3 months before the screening.
- Patients with severe chronic pulmonary diseases, including but not restricted to the patients with WHO grade III or IV pulmonary hypertension or those with chronic pulmonary diseases requiring long-term oxygen therapy.
- Patients with unstable ventricular tachycardia or ventricular fibrillation.
- Patients with poor coagulation, severe bleeding tendency or active bleeding at present.
- Patients with serious dysfunction involved in the major organs or systems (liver, kidney, gastrointestinal, cardiovascular, blood coagulation, central system, etc.) besides the respiratory system are not suitable to participate in the present study.
- Patients with a history of severe conditions in any organs or systems.
- Patients who are unable to accept other invasive rescue except cardiopulmonary resuscitation.
- Patients who are allergic to the main active ingredients or excipients of the investigational drug.
- Women who are pregnant, breastfeeding or planning to become pregnant during the study period. Woman of childbearing age who is not willing to use appropriate contraceptive methods through the completion of the clinical study.
- Patients whose participation is considered to bring significant risks to the present clinical study, cause confusion in analysis, or significantly interfere with the clinical research results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CAStem
A dose-escalation with 3 cohorts with 3 patients/cohort who receive doses of 3, 5 or 10 million cells/kg.
If there is no safety concerns for each cohort, the dose will be escalated from lower dose to next higher dose.
|
CAStem will be administered intravenously.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse reaction (AE) and severe adverse reaction (SAE)
Time Frame: Within 28 days after treatment
|
Frequency of adverse reaction (AE) and severe adverse reaction (SAE) within 28 days after treatment
|
Within 28 days after treatment
|
Changes of lung imaging examinations
Time Frame: Within 28 days after treatment
|
Evaluation by chest CT
|
Within 28 days after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to SARS-CoV-2 RT-PCR negative
Time Frame: Within 28 days after treatment
|
Marker for SARS-CoV-2
|
Within 28 days after treatment
|
Duration of fever (Celsius)
Time Frame: Within 28 days after treatment
|
The duration of a fever above 37.3 degrees Celsius
|
Within 28 days after treatment
|
Changes of blood oxygen (%)
Time Frame: Within 28 days after treatment
|
Marker for efficacy
|
Within 28 days after treatment
|
Rate of all-cause mortality within 28 days
Time Frame: Within 28 days after treatment
|
Marker for efficacy
|
Within 28 days after treatment
|
Lymphocyte count (*10^9/L)
Time Frame: Within 28 days after treatment
|
Counts of lymphocyte in a litre (L) of blood
|
Within 28 days after treatment
|
Alanine aminotransferase (U/L)
Time Frame: Within 28 days after treatment
|
Alanine aminotransferase in unit (U)/litre(L)
|
Within 28 days after treatment
|
Creatinine (umol/L)
Time Frame: Within 28 days after treatment
|
Creatinine in micromole (umol)/litre(L)
|
Within 28 days after treatment
|
Creatine kinase (U/L)
Time Frame: Within 28 days after treatment
|
Creatine kinase in U/L
|
Within 28 days after treatment
|
C-reactive protein (mg/L)
Time Frame: Within 28 days after treatment
|
C-reactive in microgram (mg)/litre(L)
|
Within 28 days after treatment
|
Procalcitonin (ng/L)
Time Frame: Within 28 days after treatment
|
Procalcitonin in nanogram (ng)/litre(L)
|
Within 28 days after treatment
|
Lactate (mmol/L)
Time Frame: Within 28 days after treatment
|
Lactate in millimole(mmol)/litre(L)
|
Within 28 days after treatment
|
IL-1beta (pg/mL)
Time Frame: Within 28 days after treatment
|
IL-1beta in picogram(pg)/millilitre(mL)
|
Within 28 days after treatment
|
IL-2 (pg/mL)
Time Frame: Within 28 days after treatment
|
IL-2 in pg/mL
|
Within 28 days after treatment
|
IL-6 (pg/mL)
Time Frame: Within 28 days after treatment
|
IL-6 in pg/mL
|
Within 28 days after treatment
|
IL-8 (pg/mL)
Time Frame: Within 28 days after treatment
|
IL-8 in pg/mL
|
Within 28 days after treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Pneumonia
- Lung Diseases
- Wounds and Injuries
- Disease
- Infant, Newborn, Diseases
- Infant, Premature, Diseases
- Thoracic Injuries
- COVID-19
- Syndrome
- Pneumonia, Viral
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
- Lung Injury
Other Study ID Numbers
- ChineseASZQ-006
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece